Compare SNAL & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNAL | ADIL |
|---|---|---|
| Founded | 2000 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 18.5M |
| IPO Year | 2022 | 2017 |
| Metric | SNAL | ADIL |
|---|---|---|
| Price | $2.27 | $4.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 20.0K | ★ 40.1K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,225,622.00 | N/A |
| Revenue This Year | $22.50 | N/A |
| Revenue Next Year | $9.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.13 |
| 52 Week High | $5.92 | $7.20 |
| Indicator | SNAL | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 28.95 | 40.12 |
| Support Level | $0.44 | $3.80 |
| Resistance Level | $2.70 | $5.08 |
| Average True Range (ATR) | 0.13 | 0.45 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 21.82 | 13.04 |
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.